Transcatheter aortic valve replacement (TAVR) with the second-generation ACURATE neo2 transcatheter heart valve (THV) showed a threefold reduction of greater-than-mild paravalvular leak and comparable technical success in comparison with the first-generation ACURATE neo, according to new registry results.